Where Will CRISPR Therapeutics Be in 10 Years?
Investor enthusiasm can wax and wane -- sometimes dramatically. Consider CRISPR Therapeutics (NASDAQ: CRSP), which is trading for around $61 a share, down from its high of $220.20 on Jan. 15, 2021.
But there is hope yet. The company is on the cusp of having its first therapy approved by the Food and Drug Administration (FDA). That therapy, exa-cel, was developed by CRISPR and Vertex Pharmaceuticals as a one-time curative treatment for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD).
Ten years from now, if the company makes this leap from a clinical-stage biotech to a commercial one, it likely will be trading for as much as $300 a share. Here's why.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
422,25 €
-0,05 %
Die Vertex Pharmaceuticals Inc. Aktie zieht viel Aufmerksamkeit auf sich: Viel mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 440 € für Vertex Pharmaceuticals Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 422.25 €.
